⚠️ Serious warning: Nothing on this website is approved by any physician. Doz is only a tool to help physicians and to search drugs easily. Taking medicines without medical supervision can be fatal.

Tezepelumab

تزپلوماب

⚠ Unverified

🌬️ Respiratory SystemAnti-TSLP antibody

🤰 Pregnancy:Use with caution 🤱 Breastfeeding:Use with caution 👶 Children:Use with caution 👴 Older adults:No specific problem stated 🇮🇷 Not found in Iran list ⛔ 1 contraindications 🇺🇸 FDA approved (BLA) BLA761224 ATC R03DX11

Market / country: 🇺🇸 USA

Tezspire (US)

🧮 Dose calculator

Disease / regimen

Asthma and chronic lung disease (reversible airflow obstruction) · Regimen source: FDA Tezspire · 2.1

Formulation

Age *

Weight (kg) (optional)

Enter age (weight is optional for this regimen).

🛡️ Safety & information

Contraindications

⛔ Hypersensitivity to tezepelumab. FDA Tezspire · 4

Warnings

• Hypersensitivity; not for acute asthma; do not stop corticosteroids abruptly; treat helminth infection before starting. FDA Tezspire · 5
• Avoid live attenuated vaccines. FDA Tezspire · 5.5

Formulations

210 mg/1.91 mL (110 mg/mL) syringe, pen or vial — injection 🇺🇸 USA FDA Tezspire · 3

👥 Special populations

🤰 PregnancyUse with caution
Label states no clear risk or has limited data; use only if needed, under medical advice. FDA Tezspire · 8.1
“Risk Summary There are no available data on TEZSPIRE use in pregnant women to evaluate for any drug-associated risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes.”
🤱 BreastfeedingUse with caution
Label: use with caution while breastfeeding; see the label text. FDA Tezspire · 8.2
“Risk Summary There is no information regarding the presence of tezepelumab-ekko in human milk, its effects on the breastfed infant, or its effects on milk production.”
👶 ChildrenUse with caution
The label has conditions, age limits or notes for children; the label sentence is quoted below. FDA Tezspire · 8.4
“Asthma The safety and effectiveness of TEZSPIRE for the add-on maintenance treatment of severe asthma have been established in pediatric patients aged 12 years and older [see Adverse Reactions (6.1) and Clinical Studies (14.1)] .”
👴 Older adultsNo specific problem stated
Label: no specific difference or dose adjustment stated for older adults. FDA Tezspire · 8.5
“No overall differences in safety or effectiveness of TEZSPIRE have been observed between patients 65 years of age and older and younger patients [see Adverse Reactions (6.1) and Clinical Studies (14.1) ] .”
⚥ Females & males of reproductive potentialNo data
The source for this drug has no section for this group.

🔗 Reference links

FDA (approval record)BLA761224
DailyMed (FDA label)FDA Tezspire
MedlinePlus (NIH)Tezepelumab Injection
WHO ATC/DDDR03DX11
Darooyab (Iran)❌ None

🇮🇷 Not found in Iran list Darooyab · search

Darooyab lists no registered dosage form or brand for this drug. This does not prove it is unavailable.

📚 Reference status for this drug

Shows which sources have references recorded for this drug and which do not.

FDA label (DailyMed)✅ Present
FDA Tezspire · 3 FDA Tezspire · 2.1 FDA Tezspire · 4 FDA Tezspire · 5 FDA Tezspire · 5.5 FDA Tezspire · SPL approval / marketing category FDA Tezspire · 8.1 FDA Tezspire · 8.2 FDA Tezspire · 8.4 FDA Tezspire · 8.5
UK SmPC (eMC / MHRA)❌ Not present
Published guideline❌ Not present
Licensed reference (medical school)❌ Not present
Iranian leaflet (IFDA)❌ Not present
Pharmacy website (secondary, unreliable)✅ Present
Darooyab · search
Clinical review⚠ Unverified